Feasibility of 2-deoxy-2-[18F]fluoro-D-glucose-A85380-PET for imaging of human cardiac nicotinic acetylcholine receptors in vivo

Clinical Research in Cardiology

Volumn 95, Issue 2, 2006, Pages 105-109

  Bucerius, J ^a   Joe, A Y ^a   Schmaljohann, J ^a   Gundisch D ^a   Minnerop, M ^a   Biersack, H J ^a   Wullner U ^a   Reinhardt, M J ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

Human heart; Multiple system atrophy; Nicotinic acetylcholine receptors; Parkinson's disease; Positron emission tomography

Indexed keywords

3 (2 AZETIDINYLMETHOXY)PYRIDINE; AMANTADINE; ANTIDEPRESSANT AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; FLUORODEOXYGLUCOSE F 18; HEART RECEPTOR; LEVODOPA; NICOTINIC RECEPTOR; RADIOLIGAND; TRACER;

ADULT; AGED; ARTICLE; BREATHING RATE; CALCULATION; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL TRIAL; DENSITY; DIAGNOSTIC IMAGING; DRUG TARGETING; DRUG UPTAKE; FEMALE; HEART DISEASE; HEART LEFT VENTRICLE; HEART RATE; HUMAN; LUNG PARENCHYMA; MALE; PARASYMPATHETIC INNERVATION; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PROTEIN LOCALIZATION; SHY DRAGER SYNDROME; STANDARD; THICKNESS; TISSUE SLICE;

AGED; FEASIBILITY STUDIES; FEMALE; FLUORODEOXYGLUCOSE F18; HEART; HEART VENTRICLES; HUMANS; MALE; MIDDLE AGED; MULTIPLE SYSTEM ATROPHY; MYOCARDIUM; PARKINSON DISEASE; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RECEPTORS, NICOTINIC;

EID: 32944460294     PISSN: 18610684     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00392-006-0342-6     Document Type: Article

References (33)

1. Bibevski S, Zhou Y, McIntosh JM, Zigmond RE, Dunlap ME (2000) Functional nicotinic acetylcholine receptors that mediate ganglionic transmission in cardiac parasympathetic neurons. J Neurosci 20:5076-5082
2. Böhm M, Maack C, Wehrlen-Grandjean M, Erdmann E, on behalf of the CIBS II Investigators (2003) Effect of bisoprolol on perioperative complications in chronic heart failure after surgery (Cardic Insufficiency Bisoprolol Study II (CIBIS II)). Z Kardiol 92:668-676
3. Buisson B, Bertrand D (1998) Open-channel blockers at the human alpha4beta2 neuronal nicotinic acetylcholine receptor. Mol Pharmacol 53:555-563
4. Druschky A, Hilz MJ, Platsch G et al (2000) Differentiation of Parkinson's disease and multiple system atrophy in early disease stages by means of I-123-MIBG-SPECT. J Neurol Sci 175:3-12
5. Fee JD, Randall WC, Wurster RD, Ardell JL (1987) Selective ganglionic blockade of vagal inputs to sinoatrial and/or atrioventricular regions. J Pharmacol Exp Ther 242:1006-1012
6. Garlichs C, Daniel WG (2000) New milestones in the therapy of chronic heart failure with beta blockers. Z Kardiol 89:236-238
7. Gilman S, Low P, Quinn N et al (1998) Consensus statement on the diagnosis of multiple system atrophy. Clin Auton Res 8:359-362
8. Goldstein DS (2003) Dysautonomia in Parkinson's disease: neurocardiological abnormalities. Lancet Neurol 2: 669-676
9. Hoppe UC, Erdmann E (2001) Guidelines for the treatment of chronic heart failure. Issued by the Executive Committee of the German Society of Cardiology - Heart and Circulation Research, compiled on behalf of the Commission of Clinical Cardiology in cooperation with Pharmaceutic Commission of the Physicians' Association. Z Kardiol 90:218-237
10. Hughes AJ, Daniel SE, Kilford L, Lees AJ (1992) Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55:181-184
11. Huonker M, Keul J (2001) Value of training-induced effects on arterial vascular system and skeletal muscles in therapy of NYHA II/III heart failure. Z Kardiol 90:813-823;
12. Erratum in Z Kardiol (2001) 90:983
13. Huth C, Friedl A, Klein H, Auricchio A (2001) Pacing therapies for congestive heart failure considering the results of the PATH-CHF study. Z Kardiol 90 (Suppl 1):10-15
14. 18F]F-A-85380: PET imaging of brain nicotinic acetylcholine receptors and whole body distribution in humans. FASEB J 17:1331-1333
15. Listerud M, Brussaard AB, Devay P, Coleman DR, Role LW (1991) Functional contribution of neuronal AchR subunits revealed by anti-sense oligonucleotides. Science [Erratum (1992) 255:12] 254:1518-1521
16. McGehee DS, Role LW (1995) Physiological diversity of nicotonic acetylcholine receptors expressed by vertebrate neurons. Annu Rev Physiol 57:521-546
17. Miller DK, Wong EH, Chesnut MD, Dwoskin LP (2002) Reboxetine: functional inhibition of monoamine transporters and nicotinic acetylcholine receptors. J Pharmacol Exp Ther 302:687-695
18. Nechwatal RM, Duck C, Gruber G (2002) Physical training as interval or continuous training in chronic heart failure for improving functional capacity, hemodynamics and quality of life - a controlled study. Z Kardiol 91:328-337
19. Patrick J, Sequela P, Vernino S, Amador M, Leutje C, Dani JA (1993) Functional diversity of neuronal nicotinic acetycholine receptors. Prog Brain Res 98:113-120
20. Poth K, Nutter TJ, Cuevas J, Parker MJ, Adams DJ, Luetje CW (1997) Heterogeneity of nicotinic receptor class and subunit mRNA expression among individual parasympathetic neurons from rat intracardiac ganglia. J Neurosci 17:586-596
21. Quik M, Bordia T, Okihara M et al (2003) L-DOPA treatment modulates nicotinic receptors in monkey striatum. Mol Pharmacol 64:619-628
22. Reinhardt MJ, Jungling FD, Krause TM, Braune S (2000) Scintigraphic differentation between two forms of primary dysautonomia early after onset of autonomic dysfunction: value of cardiac and pulmonary iodine-123 MIBG uptake. Eur J Nucl Med 27:595-600
23. Richardt G, Hartmann F, Slotty C, Katus HA (1998) Kardiale Sympathikusaktivität bei der ischämischen Herzinsuffizienz. Z Kardiol 87 (suppl 2):33-36
24. 18F]F-A85380: optimized synthesis and in vitro evaluation in Alzheimer's disease. Appl Rad Iso 61:1235-1240
25. Schmitt C (2000) Heart failure and sudden death: pharmacological and nonpharmacological treatment possibilities from the viewpoint of the rhythmologist. Z Kardiol 89 (suppl 7):55-59
26. Schnabel P, Mies F, Böhm M (1999) Hormone therapy in heart failure: growth hormone and insulin-like growth factor I. Z Kardiol 88:1-9
27. Schrader N, Erbel R, Wittlich N et al (1998) Hemodynamic effects of a single intravenous administration of prostaglandin E1 in a patient sample with chronic NYHA-stage II/III heart failure. Z Kardiol 87:683-690
28. Takatsu H, Nagashima K, Murase M et al (2000) Differentiating Parkinson's disease from multiple-system atrophy by measuring cardiac iodine-123 metaiodobenzylguanidine accumulation. JAMA 41:71-77
29. Trappe HJ, Meine M, Pfitzner P, Voigt B, Weismüller P (2001) Current aspects of defibrillator therapy in congestive heart failure. Z Kardiol 90 (suppl 1):28-34
30. 18F]fluoro-A-85380. J Nucl Med 40:1374-1380
31. Vernallis AB, Conroy WG, Berg DK (1993) Neurons assemble acetylcholine receptors with as many as three kinds of subunits while maintaining subunit segregation among receptor subtypes. Neuron 10:451-464
32. Voss B, Lange R (2001) Dynamic Cardiomyoplasty: evaluation of an alternative procedure in the treatment of terminal heart failure: Z Kardiol 90 (suppl 1):22-27
33. Weber T, Kirchgatter A, Auer J, Mayr H, Maurer E, Elber B (2000) Physical activity and training in heart failure. Z Kardiol 89:227-235